skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
MAGE-3.A1 Peptide Vaccine (Code C48632)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: MAGE-3.A1 Peptide Vaccine

Definition: A synthetic peptide cancer vaccine consisting of human leukocyte antigen HLA-A1-restricted peptide derived from human melanoma antigen 3 (MAGE-3) with potential immunostimulating and antineoplastic activities. Upon administration, MAGE-3.A1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing MAGE-3, resulting in tumor cell lysis. MAGE-3, a tumor-associated antigen (TAA), is overexpressed by a variety of cancer cell types.

Label: MAGE-3.A1 Peptide Vaccine

NCI Thesaurus Code: C48632 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL423799  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
HLA-A1-Restricted MAGE-3 Peptide Vaccine
MAGE-3.A1
MAGE-3.A1 Peptide Vaccine

External Source Codes: 
NSC Code 731578 (see NCI DTP info)
PDQ Closed Trial Search ID 685200
PDQ Open Trial Search ID 685200 (check for NCI PDQ open clinical trial info)
NCI META CUI CL423799

Other Properties:
     Name Value (qualifiers indented underneath)
code C48632
Legacy_Concept_Name HLA-A1-Restricted_MAGE-3_Peptide
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48632

Mainbox Bottom